Schering settles with SEC
This article was originally published in The Rose Sheet
Executive Summary
Schering-Plough will pay $1 mil. civil penalty to the Securities and Exchange Commission to settle allegations the firm violated Regulation Fair Disclosure, SEC announces Sept. 9. If approved, penalty will be the largest SEC has obtained from a company in violation of the law. In a separate settlement, former Schering-Plough chairman and CEO Richard Kogan agrees to pay a $50,000 civil fine to the agency, marking the first time an individual has been penalized under the reg. SEC alleged that Kogan disclosed market-sensitive information, including the firm's earnings prospects, to select investors late last year. The exec stepped down from his post in November and was replaced by Fred Hassan in April (1"The Rose Sheet" April 28, 2003, In Brief)...
You may also be interested in...
Schering CEO
Newly-appointed CEO Fred Hassan to "stabilize" and "turnaround" pharmaceutical firm's business, according to April 20 release. Former CEO of Pharmacia was widely speculated to be Schering's first choice for the post once the Pfizer/Pharmacia merger closed. Exec will face a number of challenges including Securities & Exchange Commission fair disclosure inquiry, FDA/Department of Justice investigation into good manufacturing practices in Puerto Rico. Hassan succeeds Richard Kogan, who stepped down from post in November...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.